Could diabetes drugs fix anemia in kidney disease?
NCT ID NCT07334145
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will test whether SGLT2 inhibitors, a type of diabetes drug, can help correct anemia in people with chronic kidney disease (CKD). Anemia is common in CKD and often requires iron or hormone injections, which have side effects. The trial will enroll 60 adults with CKD stages 1-4 and mild anemia, measuring changes in hemoglobin levels over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SGLT2 inhibitors (dapagliflozin or empagliflozin)
What this could lead to
If successful, this could offer a new way to manage anemia in CKD patients, potentially reducing the need for iron or ESA injections.
What could go wrong
This is a small, early-stage trial with only 60 participants. The effect on anemia may be modest or not clinically significant, and there are known risks like dehydration or diabetic ketoacidosis.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sohag University Hospital
Sohag, Sohag University, Egypt
Contact Phone: •••-•••-•••• Email: •••••@•••••